Free Trial

VolitionRx (NYSE:VNRX) Upgraded to Strong-Buy at Jones Trading

VolitionRx logo with Medical background

Jones Trading upgraded shares of VolitionRx (NYSE:VNRX - Free Report) to a strong-buy rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has $3.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright started coverage on VolitionRx in a research note on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price target for the company. D. Boral Capital reissued a "buy" rating and set a $5.00 target price on shares of VolitionRx in a research note on Wednesday, April 30th. Finally, Wall Street Zen initiated coverage on shares of VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $3.50.

Read Our Latest Stock Report on VNRX

VolitionRx Stock Performance

Shares of VNRX traded up $0.04 during mid-day trading on Tuesday, reaching $0.64. 701,938 shares of the company's stock traded hands, compared to its average volume of 193,403. The business's 50-day moving average price is $0.50 and its 200-day moving average price is $0.57. The stock has a market capitalization of $65.50 million, a P/E ratio of -1.77 and a beta of 1.07. VolitionRx has a 12 month low of $0.40 and a 12 month high of $0.90.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of VolitionRx stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the acquisition, the chief executive officer now owns 2,299,222 shares of the company's stock, valued at approximately $1,264,572.10. This represents a 8.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 271,818 shares of company stock valued at $141,100 over the last three months. Company insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Lagoda Investment Management L.P. boosted its stake in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $36,000. Finally, Two Sigma Securities LLC acquired a new position in shares of VolitionRx in the 4th quarter valued at $29,000. Institutional investors own 8.09% of the company's stock.

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More

Should You Invest $1,000 in VolitionRx Right Now?

Before you consider VolitionRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.

While VolitionRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025
3 Defense Stocks Under $10 With Massive Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines